Wenger Vieli Advises Xeltis on €50 Million Financing Round

"Wenger Vieli advised medtech company Xeltis on a financing round that raised approximately €50 million, including up to €37.5 million from the European Investment Bank and €10 million from existing shareholders such as EQT Life Sciences and Invest-NL. Proceeds will fund the launch of a new vascular access implant for dialysis patients."

Wenger Vieli represented medtech company Xeltis in connection with its recent financing round. The transaction raised approximately EUR 50 million in total. The sum includes up to EUR 37.5 million from the European Investment Bank (EIB) and EUR 10 million from existing shareholders, among them EQT Life Sciences and Invest-NL. Xeltis intends to use the proceeds to introduce a new type of vascular implant designed to provide reliable blood access for patients undergoing kidney dialysis. Wenger Vieli represented Xeltis with a team composed by: Partner Beat Speck (corporate/M&A) led the Wenger Vieli team on the matter, working alongside counsels Jonas Bühlmann (tax) and Micha Schilling (financing), as well as associates Fabienne Nufer (corporate/M&A) and Dario Schönbächler (corporate/M&A).

Wenger Vieli Advises Xeltis on €50 Million Financing Round

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads